Objective
Type 1 diabetes (T1D) occurs when the immune system destroys the pancreas’s insulin-producing cells, necessitating lifelong insulin therapy. While current treatments are life-saving, they cannot perfectly mimic the body’s natural glucose control. This study aims to develop a safer, more effective cell-replacement therapy that restores natural insulin production and reduces the burden of daily disease management.
The main objectives are:
1. Develop invisible" islets: We will create insulin-producing islets from stem cells engineered to evade immune detection. By "shielding" these cells from the patient's immune system, we aim to ensure their long-term survival and eliminate the need for harsh anti-rejection drugs.
2. Establish a built-in blood supply: To prevent transplanted cells from "suffocating" before the body can reach them, we will combine islets with vascular progenitor cells. These cells act as a biological plumbing system, jumpstarting blood vessel formation to provide immediate oxygen and nutrients.
3. Provide a protective "nest" for growth: We will use a biodegradable, 3D-printed scaffold to house the cell clusters. This structure provides a stable environment that encourages the patient's own blood vessels to grow into the transplant quickly and efficiently.
4. Real-time monitoring of success: We will use non-invasive, high-tech imaging to track blood flow into the transplant. This allows us to monitor how well the cells are integrating with the body in real-time, providing an early "health check" on the therapy’s performance.
Summary: By combining immune protection with rapid blood vessel integration, this project seeks to transform stem cell-derived islets into a reliable, "off-the-shelf" cure that restores natural insulin production for people living with T1D.
Background Rationale
Type 1 diabetes (T1D) is a chronic autoimmune disease where the body’s immune system mistakenly destroys the insulin-producing islets in the pancreas. Without insulin to regulate blood sugar, patients must rely on lifelong injections or pumps. While these treatments are life-saving, they cannot fully replicate the body’s natural ability to maintain perfect glucose levels, leaving many at risk for devastating complications like heart disease, kidney failure, and vision loss.
The challenge of cell replacement:
The most promising approach to a cure is transplanting healthy insulin-producing cells. However, this strategy currently faces three major hurdles:
1. Supply shortage: There are not enough organ donors to treat the millions of people living with T1D.
2. Immune rejection: The body sees transplanted cells as "foreign," requiring patients to take lifelong, toxic anti-rejection drugs.
3. The "Ischemic Gap": Most transplanted cells die within days because they lack an immediate blood supply. They essentially "suffocate" before the body can grow new vessels to reach them.
Our proposed solution is an integrated perfusion-ready platform:
Our research at the Cedars-Sinai Biomanufacturing Center addresses these hurdles through a unified cell-engineering and delivery platform.
• Unlimited cell supply: By using laboratory-grown stem cells, we can manufacture a consistent and unlimited supply of high-quality islets.
• "Invisible" protection: We use advanced genetic engineering to make these cells "invisible" to the immune system. By removing the markers that trigger a "foreign" alert and adding protective signals, we aim to eliminate the need for harsh anti-rejection drugs.
• A built-in blood supply: To bridge the "Ischemic Gap," we combine the islets with supportive vascular cells. These act like a biological plumbing system, ready to connect to the patient's blood supply immediately.
• Specialized support structure: These cells are housed in a high-porosity, 3D-printed scaffold. This "nest" provides structural support and is specifically designed to encourage the body's own blood vessels to grow into the transplant rapidly.
Rationale for the future: By solving the twin problems of immune rejection and early cell death, we are building a "perfusion-ready" therapy. This project provides the foundation for an "off-the-shelf" cure—a scalable, reliable treatment that can be delivered to any patient to restore natural insulin production and transform life with T1D.
Description of Project
Type 1 diabetes (T1D) is a lifelong autoimmune disease where the body’s immune system mistakenly destroys the insulin-producing islets (β-cells ) in the pancreas. Without insulin to regulate blood sugar, individuals must rely on constant monitoring and daily injections. While these treatments are life-saving, they cannot replicate the near-perfect glucose control of healthy islets, leaving patients at risk for long-term complications like heart disease and kidney failure.
A promising cure is cell replacement therapy—transplanting new islets to restore natural insulin production. While organ transplants from donors have worked, they are limited by a severe shortage of available organs and the need for toxic, lifelong anti-rejection drugs.
Our research at the Cedars-Sinai Biomanufacturing Center addresses these challenges by creating a next-generation, "off-the-shelf" therapy that integrates three major innovations: immune-evasive cells, vascular support, and advanced scaffolding.
1. "Invisible" Islets: We have engineered stem cells to be "invisible" to the immune system. By removing the markers that trigger a "foreign" alert and adding "don’t eat me" signals, these cells can survive after transplantation without the need for harsh anti-rejection drugs.
2. A built-in blood supply: A major reason transplants fail is that the new cells "suffocate" before the body can grow blood vessels to reach them. We solve this by pre-mixing our islets with vascular progenitor cells. These act like a built-in plumbing system, ready to connect to the patient's blood supply immediately after surgery.
3. The "Fluffy-X™" support system: We place these cell clusters inside a highly porous, 3D-printed scaffold. This biodegradable structure acts like a protective nest, keeping the cells in place while encouraging the body to grow new blood vessels into the transplant rapidly.
To ensure the transplant is working, we will use a high-tech, non-invasive imaging tool called Laser Speckle Contrast Imaging to watch blood flow through the transplant in real-time. This allows us to confirm the cells are receiving the oxygen they need to thrive.
Impact: By combining "shielded" immune evasion with rapid vascular integration, we are building a scalable, ready-to-use therapy. Our goal is to move beyond daily injections and provide a long-term, potentially curative treatment that restores freedom and health to millions of people living with T1D.
Anticipated Outcome
The anticipated outcome of this research is a significant leap toward a functional cure for Type 1 diabetes (T1D). By solving the two greatest challenges in the field—immune rejection and early cell death—this project aims to deliver a durable and scalable cell-based therapy.
The expected results of this work include:
• Long-term survival without anti-rejection drugs: We anticipate that our "invisible" insulin-producing islets will successfully evade the patient’s immune system. If these engineered cells function as intended, they could survive indefinitely after transplantation without the need for lifelong, toxic immunosuppressive medications, making cell therapy safer and available to a much broader population.
• Rapid connection to the blood supply: By including supportive vascular cells, we expect to bridge the critical "oxygen gap" that currently causes most transplanted cells to die. We anticipate that these cells will act as a biological plumbing system, allowing the new islets to receive life-sustaining oxygen and nutrients within hours, not weeks, of transplantation.
• A fully Integrated, living graft: Using a biodegradable 3D scaffold, we expect to see the transplanted cells organize into a stable, functional tissue. As the scaffold safely dissolves over time, it will leave behind a permanent, healthy "island" of cells that are fully integrated with the body’s own blood vessels and capable of precise blood sugar control.
• A "Health Check" for transplants: We aim to prove that high-tech, non-invasive imaging can accurately predict the success of a transplant. By measuring blood flow in real-time, we anticipate establishing a "gold standard" for monitoring graft health, allowing doctors to confirm that a transplant has successfully integrated and is functioning as expected.
The big picture:
Ultimately, this work is expected to provide a reliable and scalable platform for treating T1D. If successful, this research will move us away from daily insulin injections and toward a future where a single, "off-the-shelf" transplant can restore natural insulin production and provide long-lasting freedom from the daily burden of the disease.
Relevance to T1D
This research is fundamentally relevant to Type 1 Diabetes (T1D) because it targets the underlying cause of the disease—the loss of insulin-producing cells—rather than just treating the symptoms. By moving beyond insulin injections and pumps, this work aims to restore the body’s natural ability to regulate blood sugar.
Overcoming the scarcity of treatment: Currently, transplanting donor islets is a proven way to restore insulin production, but it is limited by a critical shortage of organ donors. Our approach uses laboratory-grown stem cells to provide an unlimited and renewable supply of high-quality islets. This scalability is essential for making cell-replacement therapy a realistic option for the millions of people living with T1D, rather than just a select few.
Breaking the barrier of chronic medication: A major deterrent for current islet transplantation is the need for lifelong, toxic anti-rejection drugs. This project is highly relevant because it utilizes genetically "invisible" islets designed to survive without triggering an immune attack. By eliminating the need for immunosuppression, we can make transplantation a safer and more accessible option for a much broader range of patients, including children and those with early-stage T1D.
Ensuring successful outcomes: The relevance of this study also lies in its focus on long-term cell survival. By including supportive vascular cells and a specialized delivery structure, we address the common failure where transplanted cells die shortly after surgery due to a lack of oxygen. Establishing a "perfusion-ready" graft ensures that the new islets can immediately begin their life-saving work.
Conclusion: Ultimately, this work is relevant because it seeks to bridge the gap between scientific discovery and a clinical cure. By addressing immune protection and blood supply in a single, unified platform, this research paves the way for a durable, "off-the-shelf" treatment that restores freedom and health to the T1D community.